University of Lausanne

Mutual funds and safe government bonds: do returns matter?

Retrieved on: 
星期四, 四月 25, 2024
ACT, Safe Haven, Research Papers in Economics, Flight, Policy, B.3, ICAPM, RT, Journal of International Economics, Krishnamurti, Business, CIP, International, Observation, P25, Safety, A23, Benchmarking, B.2, FX, Paper, TSD, Environment, Journal of Financial Economics, Bogdanov, Federal, Website, United, A14, Total, The Economic Journal, Eurozone, Face, G11, Quarterly Journal of Economics, Interest rate parity, History, WD, Investment, Liquidity premium, Politics, OLS, Statistics, G15, Caballero, PDF, Classification, ECB, Foreign exchange market, AC, P99, Federal funds, Froot, Lethargy, Social science, Interest, JEL, Bias, Journal, Research, Journal of Economic Literature, The Journal of Finance, E.3, Literature, Federal Reserve, Parity, European Central Bank, AA, Annual Review, Growth, Bank of England, FRED, S&P, Injection, Risk, Elasticity, Government, G12, Finance, BIS, S1, JL, E.1, Money, Depreciation, Asset, Treasury, Federal Reserve Economic Data, A11, A10, R2, Section 4, UMP, A4, Boj, Section 3, Accounting, SJ, Fed, Mutual fund, Lustig, University of Lausanne, Section 2, P75, Foreign-exchange reserves of India, Assets under management, A19, GBP, FE, American Economic Review, A22, E.5, A3, A21, Flight-to-liquidity, Aggregate demand, G23, WT, USD, Autocorrelation, CAD, UIP, Currency, XR, Quarterly Journal, Appendix H, Capital, P95, A6, Zhu, University, B.1, P50, CHF, Transmission, Swings, Estate (law), EUR, Bank for International Settlements, JPY, E.4, Central bank, Multicollinearity, Bank, Fixed effects model, Reproduction, CAP, The Atlanta Jewish Times, VIX, Data, Om, Lobster
Key Points: 

    Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

    Retrieved on: 
    星期三, 九月 20, 2023
    Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

    We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

    Key Points: 
    • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
    • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
    • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
    • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

    Sparx Biopharmaceutical Welcomes Dr. Roland Meier as Chief Medical Officer

    Retrieved on: 
    星期二, 九月 5, 2023
    University of Zurich, University, University of California, Berkeley, Blas, Biotechnology, Sparx, Eli Lilly, Kyowa Kirin, UC, Patent, Cancer, Knowledge, ADC, University of Lausanne, Fine chemical, Pharmaceutical industry

    CHICAGO, Sept. 5, 2023 /PRNewswire/ -- Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces the addition of Dr. Roland Meier as their esteemed Chief Medical Officer.

    Key Points: 
    • CHICAGO, Sept. 5, 2023 /PRNewswire/ -- Spearheading the field of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces the addition of Dr. Roland Meier as their esteemed Chief Medical Officer.
    • Dr. Guidong Zhu, CEO and founder of SparX, commented, "Dr. Meier's esteemed reputation in immuno-oncology drug development is unparalleled.
    • With Roland on board, we are poised to transition SparX from a discovery-centric to a clinical-driven biotech entity."
    • On becoming a part of the SparX family, Dr. Meier shared, "SparX exemplifies innovation in biotechnology.

    RaySearch to present the latest advances in RayStation, RayCare and RayIntelligence at AAPM 2023

    Retrieved on: 
    星期一, 七月 24, 2023
    Photon, LET, Health, AAPM, RaySearch Laboratories, DICOM, Research, Lausanne University Hospital, Doctor of Philosophy, Véronique, University of Lausanne, Congress, Linear energy transfer, Medical imaging

    STOCKHOLM, July 23, 2023 /PRNewswire/ -- The latest version of RayStation includes among others support for automatic field-in-field planning for photons, a method that generates homogeneous and conformal dose distributions by combining a few subfields, as well as point-based optimization of brachy plans, and faster loading of data. Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning. Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.

    Key Points: 
    • RaySearch will be showcasing the latest software innovations at AAPM in Houston, Texas, July 23-27.
    • Attendees will be able to book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and the cloud-based oncology analytics system RayIntelligence® during the congress.
    • Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning.
    • Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.

    Emergex Reports Promising Data from Completed Swiss Phase I Trial of CoronaTcP™, T Cell-Priming Immune Set-Point Candidate for Betacoronaviruses

    Retrieved on: 
    星期三, 七月 19, 2023
    Volunteering, University, Dengue fever, SARS-CoV-2, Lausanne, COVID-19, Infection, RNA, CHUV, University of Lausanne, Gold, Orthornavirae, Peptide, Entrepreneurship, Disease, Safety, Vaccine, Betacoronavirus

    Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.

    Key Points: 
    • Assessment of primary outcome measures of the trial indicate that CoronaTcP showed a favourable safety profile, with no treatment-related serious adverse events observed.
    • There was no systematic difference between groups that received high or low dose CoronaTcP, in terms of overall safety or reactogenicity.
    • In secondary immunogenicity analyses, the assessment of baseline levels of SARS-CoV-2-specific anti-nucleoprotein antibodies indicated most participants had experienced previous SARS-CoV-2 infection.
    • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer, Emergex, said: “The positive data from both clinical trials – naNO-DENGUE and naNO-COVID - represent an important landmark for Emergex.

    RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

    Retrieved on: 
    星期一, 七月 10, 2023
    Cyberknife, Partnership, Accuray, RaySearch Laboratories, CHUV, University of Lausanne, FLASH, Patient, Health, Safety, Lausanne University Hospital, Software, Medical imaging, Nursing

    STOCKHOLM, July 10, 2023 /PRNewswire/ -- The first treatment - for a patient with brain metastasis - was successfully carried out on June 9.

    Key Points: 
    • RaySearch Laboratories AB (publ) announces that Lausanne Univeristy Hospital (CHUV), Switzerland, has treated their first patient using RayStation®* treatment planning system together with the oncology information system RayCare®* in combination with the Accuray CyberKnife® treatment delivery system.
    • Lausanne University Hospital (CHUV) has been a RaySearch customer since 2017.
    • At the same time the hospital also decided to invest in RayCare and RaySearch's oncology analytics system RayIntelligence.
    • Taking RayCare in clinical use with CyberKnife is an important step forward in this program.

    IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas

    Retrieved on: 
    星期五, 五月 12, 2023
    Oncology, Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Electron, University, Intraoperative electron radiation therapy, Therapeutic index, Toxicity, Medicine, SOC, Radiation therapy, Sale, CHUV, University of Lausanne, Teaching hospital, US, Radiation, LINAC, FLASH, Patient, Standard of care, NMSC, Safety, Lausanne University Hospital, Pharmaceutical industry, Medical imaging, Dermatology

    It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).

    Key Points: 
    • It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
    • It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator (LINAC).
    • “This feels like a breakthrough moment in our collective study of the role and effectiveness of FLASH radiotherapy as compared to standard of care radiotherapy.
    • *Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.

    IntraOp Medical Corporation Announces Their 10th Mobetron with FLASH-IQ Installation Worldwide

    Retrieved on: 
    星期四, 五月 11, 2023
    Radiology, Biotechnology, Oncology, General Health, Health, Medical Devices, Hospitals, Health Technology, University, Intraoperative electron radiation therapy, CHUM, Cancer, Research, University of Wisconsin Carbone Cancer Center, Sale, CHUV, University of Lausanne, MD Anderson Cancer Center, Radiation therapy, Radiation, FLASH, Patient, NMSC, Ultra, Growth, Ides, Lausanne University Hospital, Pharmaceutical industry, Nightclub

    IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.

    Key Points: 
    • IntraOp Medical Corporation proudly announces that its IntraOp® Mobetron® with FLASH-IQ™ technology will soon be installed in its tenth institution worldwide, marking a significant milestone in the study of FLASH radiotherapy.
    • IntraOp Mobetron with FLASH-IQ is a novel radiotherapy platform capable of delivering an Ultra-High Dose Rate (UHDR) electron beam.
    • Several additional sites are applying for IDEs in the US, along with Canada, Belgium and Germany applying for similar exemptions in their countries.
    • IntraOp supports these applications and looks forward to the continued growth and development in the study of FLASH radiotherapy.

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

    Retrieved on: 
    星期三, 五月 10, 2023
    Molecular biology, The Elements of Style, Journal of Thoracic Oncology, Internet Technical Committee, Law, Lung cancer, Oncology, Article, Doctor of Philosophy, European Society for Medical Oncology, Audit committee, Teaching hospital, Professor, Retirement, Journal, University Hospital (Newark, New Jersey), Ageing, Health, Ludwig Cancer Research, Annals of Oncology, Swiss, SIX Swiss Exchange, Teaching, International Association, Research, Attention, Annals, Security (finance), Editor-in-chief, Woman, Swiss Federal Institute of Technology, ESMO, Medicine, NSCLC, US, HKEX, Letter, Swiss Federal Institute of Aquatic Science and Technology, Part, University of Lausanne, Galenica, Strategic Advisory Board for Intellectual Property Policy, HK, Management, Nursing

    The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

    Key Points: 
    • The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.
    • Mr Simon To, Chairman of HUTCHMED said “On behalf of the Board, I would like to extend a warm welcome to Professor Peters to the Company.
    • Professor Peters is also an independent director of Galenica AG, which is listed on the SIX Swiss Exchange.
    • The director’s fees of Professor Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company under her appointment letter are US$76,000, US$8,000 and US$13,500 per annum respectively.

    Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

    Retrieved on: 
    星期四, 三月 9, 2023
    Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Swiss Cancer League, MD, Virology, McGill University, University School, The Ottawa Hospital, Oklahoma State University College of Agricultural Sciences and Natural Resources, Jennerex, Journal, CD8, Therapy, Euronext Paris, University of Ottawa Faculty of Medicine, Ottawa Hospital Research Institute, Research, School, OHRI, Medical Research Council, Potyvirus, Publication, New York University Grossman School of Medicine, National university, Agriculture Network Information Center, Clinical, Biochemistry, University, LICR, CTL, Immunotherapy, University of Lausanne, OV, Faculty, Doctor of Philosophy, Medical Research Council (United Kingdom), Épalinges, Ludwig Cancer Research, McMaster University, Pharmaceutical industry, Science, Medicine, Biology, Cancer, Nature

    Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.

    Key Points: 
    • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.
    • “John and Pedro are world leaders in cancer immunotherapy, and will bring considerable expertise to Transgene,” said Hedi Ben Brahim, Transgene’s CEO.
    • He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics.
    • Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.